Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure

U.S. guidelines recommend consideration of sacubitril/valsartan in chronic heart failure (HF) and mildly reduced or preserved ejection fraction (EF). Whether initiation is safe and effective in EF >40% after a worsening heart failure (WHF) event is unknown. PARAGLIDE-HF (Prospective comparison of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2023-07, Vol.82 (1), p.1-12
Hauptverfasser:	Mentz, Robert J., Ward, Jonathan H., Hernandez, Adrian F., Lepage, Serge, Morrow, David A., Sarwat, Samiha, Sharma, Kavita, Starling, Randall C., Velazquez, Eric J., Williamson, Kristin M., Desai, Akshay S., Zieroth, Shelley, Solomon, Scott D., Braunwald, Eugene
Format:	Artikel
Sprache:	eng
Schlagworte:	acute decompensated HFpEF Aminobutyrates - pharmacology Aminobutyrates - therapeutic use Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Angiotensins - pharmacology Angiotensins - therapeutic use Biphenyl Compounds - therapeutic use clinical outcomes Drug Combinations Heart Failure HFmrEF Humans Hypotension - chemically induced Hypotension - drug therapy natriuretic peptides Neprilysin - therapeutic use sacubitril/valsartan Stroke Volume Tetrazoles - pharmacology Tetrazoles - therapeutic use Valsartan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!